The second meta-analysis showed instead that treatment with metformin (OR 0.74), DPP-4is (OR 0.88), SGLT-2is (OR 0.82), and GLP-1 RAs (OR 0.91) was related to reduced COVID-19 mortality rates in T2DM subjects, while insulin to increased mortality [42]. This evidence concerns the gene GLP1R and COVID-19.